In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Rallybio (RLYB – Research Report), with a price target of $29.00. The company’s shares closed last Tuesday at $10.65.
According to TipRanks.com, Wolleben is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -31.0% and a 13.7% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rallybio with a $31.67 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $25.78 and a one-year low of $6.74. Currently, Rallybio has an average volume of 127.4K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RLYB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Read More on RLYB:
